Editing Lipoxin (section)

==History==
LXA<sub>4</sub> and LXB<sub>4</sub> were first described by [[Charles N. Serhan|Charles Serhan]], Mats Hamberg, and [[Bengt I. Samuelsson|Bengt Samuelsson]] in 1984.<ref name="pmid6422933">{{cite journal | vauthors = Serhan CN, Hamberg M, Samuelsson B | title = Trihydroxytetraenes: a novel series of compounds formed from arachidonic acid in human leukocytes | journal = Biochemical and Biophysical Research Communications | volume = 118 | issue = 3 | pages = 943–9 | year = 1984 | pmid = 6422933 | doi = 10.1016/0006-291x(84)91486-4}}</ref>  They reported that human blood [[neutrophil]]s, when stimulated, make these two lipoxins and that neutrophils, when stimulated by either of the LXs, mounted [[superoxide]] anion (O<sub>2</sub><sup>&minus;</sup>) generation and [[degranulation]] responses. Both responses are considered to be pro-inflammatory in that, while aimed at neutralizing invading pathogens and digesting foreign material, can contribute to damaging host tissues and thereby prolonging and promoting further inflammation. Subsequent studies, however, found that these lipoxins, as well as their epimers, epi-LXA<sub>4</sub> and LXB<sub>4</sub>, act primarily to dampen and resolve inflammation, i.e. they are anti-inflammatory [[cell signaling]] agents.